• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Vedolizumab, a gut-specific monoclonal antibody, renews hope for an alternative to anti-TNF therapy in inflammatory bowel diseases.

作者信息

Rezaie Ali

机构信息

Division of Gastroenterology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA.

出版信息

Ann Gastroenterol. 2014;27(2):179-180.

PMID:24733411
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3982639/
Abstract
摘要

相似文献

1
Vedolizumab, a gut-specific monoclonal antibody, renews hope for an alternative to anti-TNF therapy in inflammatory bowel diseases.维多珠单抗，一种肠道特异性单克隆抗体，为炎症性肠病中抗TNF治疗的替代方案带来了新的希望。
Ann Gastroenterol. 2014;27(2):179-180.
2
Vedolizumab is an effective alternative in inflammatory bowel disease patients with anti-TNF-alpha therapy-induced dermatological side effects.维多珠单抗是患有抗TNF-α治疗引起的皮肤副作用的炎症性肠病患者的有效替代药物。
Dig Liver Dis. 2016 Nov;48(11):1391-1393. doi: 10.1016/j.dld.2016.08.122. Epub 2016 Sep 1.
3
Systemic Chemokine Levels with "Gut-Specific" Vedolizumab in Patients with Inflammatory Bowel Disease-A Pilot Study.炎症性肠病患者使用“肠道特异性”维多珠单抗后的全身趋化因子水平——一项初步研究
Int J Mol Sci. 2017 Aug 22;18(8):1827. doi: 10.3390/ijms18081827.
4
Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.比较抗 TNF 药物与维得利珠单抗作为炎症性肠病二线生物治疗药物的药物生存：来自全国瑞典登记处的结果。
Aliment Pharmacol Ther. 2021 Feb;53(4):471-483. doi: 10.1111/apt.16193. Epub 2020 Dec 19.
5
The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.维多珠单抗（一种正在研发用于治疗炎症性肠病的抗α4β7整合素治疗性抗体）的结合特异性和选择性拮抗作用。
J Pharmacol Exp Ther. 2009 Sep;330(3):864-75. doi: 10.1124/jpet.109.153973. Epub 2009 Jun 9.
6
Postoperative outcomes in vedolizumab-treated pediatric patients undergoing abdominal operations for inflammatory bowel disease.接受维多珠单抗治疗的炎性肠病患儿腹部手术后的结局
J Pediatr Surg. 2018 Sep;53(9):1706-1709. doi: 10.1016/j.jpedsurg.2017.09.019. Epub 2017 Oct 9.
7
A product review of vedolizumab in inflammatory bowel disease.维得利珠单抗治疗炎症性肠病的产品评价。
Hum Vaccin Immunother. 2019;15(10):2482-2490. doi: 10.1080/21645515.2019.1591139. Epub 2019 May 7.
8
Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study.接受vedolizumab 治疗的炎症性肠病患者行大型腹部手术的术后结局：回顾性多中心队列研究。
Inflamm Bowel Dis. 2018 Mar 19;24(4):871-876. doi: 10.1093/ibd/izx076.
9
Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases.生物制剂初治炎症性肠病患者使用维得利珠单抗的快速应答。
Clin Gastroenterol Hepatol. 2019 Jan;17(1):130-138.e7. doi: 10.1016/j.cgh.2018.05.026. Epub 2018 May 29.
10
Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases.维多珠单抗治疗与改善炎症性肠病患者的睡眠质量和情绪有关。
Dig Dis Sci. 2017 Jan;62(1):197-206. doi: 10.1007/s10620-016-4356-2. Epub 2016 Oct 28.

引用本文的文献

1
Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.在炎症性肠病儿科患者中使用维得利珠单抗的安全性和有效性：一项观察性多中心西班牙研究。
Eur J Pediatr. 2021 Sep;180(9):3029-3038. doi: 10.1007/s00431-021-04063-6. Epub 2021 Apr 20.
2
Positioning Therapy for Ulcerative Colitis.溃疡性结肠炎的定位治疗
Curr Gastroenterol Rep. 2015 Aug;17(8):29. doi: 10.1007/s11894-015-0454-0.

本文引用的文献

1
Vedolizumab for the treatment of IBD: a selective therapeutic approach targeting pathogenic a4b7 cells.维得利珠单抗治疗炎症性肠病：针对致病性 a4b7 细胞的选择性治疗方法。
Curr Drug Targets. 2013 Nov;14(12):1433-43. doi: 10.2174/13894501113146660206.
2
Vedolizumab as induction and maintenance therapy for Crohn's disease.维得利珠单抗作为克罗恩病的诱导缓解和维持治疗药物。
N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739.
3
Vedolizumab as induction and maintenance therapy for ulcerative colitis.维得利珠单抗用于溃疡性结肠炎的诱导缓解和维持治疗。
N Engl J Med. 2013 Aug 22;369(8):699-710. doi: 10.1056/NEJMoa1215734.
4
Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies.炎症性肠病手术风险随时间推移而降低：基于人群的系统评价和荟萃分析。
Gastroenterology. 2013 Nov;145(5):996-1006. doi: 10.1053/j.gastro.2013.07.041. Epub 2013 Jul 27.
5
The future of inflammatory bowel disease therapy: where do we go from here?炎症性肠病治疗的未来：我们从何处去？
Dig Dis. 2012;30 Suppl 3:140-4. doi: 10.1159/000342742. Epub 2013 Jan 3.